|
 |
AlprostadilThis page contains recent news articles, when available, and an overview of Alprostadil but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. ... PR Newswire (press release) Stock Watch: GNAU, ERFW, NEXM & OPGM - Dec 21, 2009 ...including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil ... TMCnet www.PicksThatMove.com: "Picks that move" Alerts, December 18, 2009: SENO, AIRV ... - Dec 18, 2009 ...including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil ... TMCnet NexMed agrees to lease E. Windsor facility - Dec 17, 2009 By João-Pierre Ruth NexMed Inc., a clinical research organization moving from East Windsor to San Diego, said Thursday it agreed to lease out the New Jersey ... NJBIZ PennyStockChaser.com: Pennystockchaser.com: www.pennnystockchaser.com: Penny ... - Dec 17, 2009 ...including a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 alprostadil ... Trading Markets (press release) Consult specialist to tackle dysfunction problem - Dec 14, 2009 Another drug, alprostadil, is a synthetic version of the hormone prostaglandin E. The hormone helps relax muscle tissue in the penis, which enhances the ... Danbury News Times www.StockMarketingInc.com: www.StockMarketingInc.com presents: Tuesday's ... - Dec 15, 2009 NexMed's pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, ... Trading Markets (press release) NexMed Receives Cash Infusion of $750000 - Nov 11, 2009 NexMed's pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, ... Business Wire (press release) NexMed Announces Third Quarter 2009 Financial Results Conference Call - Nov 5, 2009 About NexMed NexMed`s pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, ... Reuters VIVUS to Present at Lazard Capital Markets Healthcare Conference - Nov 11, 2009 MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. ... CNNMoney.com (press release) NexMed Confirms Nasdaq Hearing Date - Oct 20, 2009 About NexMed NexMed`s pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, ... Reuters VIVUS To Present at Merriman Curhan Ford's Investor Summit - Nov 5, 2009 MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. ... Reuters VIVUS Reports Third Quarter 2009 Highlights and Financial Results - Nov 3, 2009 MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. ... Reuters Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity ... - Oct 29, 2009 MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. ... Reuters |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
